Market Access News | pharmaphorum

News

HCP with a small pile of pills in their palm

NICE relents, ending postcode access to prostate cancer drug

Men in England with high-risk prostate cancer will soon be able to get treatment with a drug available in Scotland and Wales for almost three years.

News

'Skinny' generic Vascepa label case reaches US Supreme Court

SCOTUS has agreed to hear a patent dispute between Amarin and Hikma that could have implications for 'skinny labels' used by generic manufacturers.

News

Trump's affordability plan arrives, built around MFN pricing

Trump has finally delivered his healthcare proposals, but it seems the 'concept of a plan' promised for many years remains pretty much just that.

News

A globe atlas from above on a white surface

Novartis issues a life sciences warning in a 'G-Zero' world

Novartis claims life sciences lie at the centre of a shift in geopolitics and policies in regions like Europe, Japan, and Canada are "self-defeating."

News

FDA seeks changes to GLP-1, flu shot labels

The FDA has asked manufacturers of GLP-1 drugs used for weight loss to remove warnings of suicidal thinking, but added warnings to flu shots.

News

Sentynl gets first FDA approval for rare disease Menkes

Children with a devastating, rare disorder of copper metabolism, called Menkes disease, now have an FDA-approved treatment for the first time.

NICE relents, ending postcode access to prostate cancer drug

'Skinny' generic Vascepa label case reaches US Supreme Court

Trump's affordability plan arrives, built around MFN pricing

Novartis issues a life sciences warning in a 'G-Zero' world

FDA seeks changes to GLP-1, flu shot labels

Sentynl gets first FDA approval for rare disease Menkes

Trial miss doesn't dent Biogen's faith in Alzheimer's drug

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks